Cascadian Therapeutics (Formally known as Oncothyreon)
2601 Fourth Avenue
Suite 500
Seattle
Washington
98121
United States
Tel: 206-801-2100
Fax: 206-801-2101
Website: http://www.cascadianrx.com/
233 articles with Cascadian Therapeutics (Formally known as Oncothyreon)
-
BioSpace Movers and Shakers for Oct. 15
10/15/2018
Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies. -
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
-
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
-
Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics
3/9/2018
Seattle Genetics expects to complete today the acquisition of Cascadian Therapeutics through a merger without a vote of Cascadian Therapeutics stockholders pursuant to Section 251(h) of the Delaware General Corporation Law.
-
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
-
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
-
Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc.
2/9/2018
Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc. (NASDAQ:CASC) at a price of $10.00 per share net to the seller in cash, without interest, less any applicable withholding taxes (the “Offer”).
-
Seattle Genetics is paying $10 per share in cash for Cascadian.
-
Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
1/4/2018
A look at the accomplishments that occurred during the fourth quarter of 2017.
-
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From the European Medicines Agency
1/2/2018
This removes the requirement for pediatric clinical studies to support tucatinib market authorization application for treatment of metastatic breast cancer in Europe.
-
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index
12/13/2017
This will become effective prior to U.S. market open on Monday, December 18, 2017.
-
Prolonged Progression-Free Survival Reinforces Cascadian Therapeutics' Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
12/8/2017
Results from this analysis will be presented in a poster session at the 2017 San Antonio Breast Cancer Symposium on Friday, December 8, 2017 beginning at 5:00 p.m. CST.
-
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
11/9/2017
Cash, cash equivalents and investments totaled $113.0 million as of September 30, 2017, compared to $62.8 million at December 31, 2016.
-
Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017
11/1/2017
Management will host a conference call and live audio webcast to discuss the results and provide a general corporate update
-
Indalo Therapeutics Formed by Merger of Antegrin and Cascadia
10/17/2017
Financial terms of the deal were not disclosed.
-
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted To Tucatinib For The Treatment Of HER2+ Metastatic Colorectal Cancer
9/27/2017
-
Cascadian Therapeutics Release: Tucatinib Data In Multiple Tumor Types Presented At The European Society For Medical Oncology (ESMO) 2017 Congress
9/11/2017
-
Cascadian Therapeutics Reports Second Quarter 2017 Financial Results
8/9/2017
-
Cascadian Therapeutics To Report Second Quarter 2017 Financial Results On August 8, 2017
8/1/2017
-
Cascadian Therapeutics Announces Positive Regulatory Update For Tucatinib In Europe
7/11/2017